BioSpace News Archive

According to Vision Research Reports, the Cell And Gene Therapy Clinical Trials market size is expected to hit around US$ 48.4 billion by 2030 and is anticipated to grow at a CAGR of 24.3% during forecast period 2021 to 2030.

The global clinical trial packaging market is expected to grow at a CAGR of 7.5% during the forecast period 2021 to 2030. The clinical trial packaging market is estimated to be driven by rising clinical trial activities coupled with rapid adoption of contract manufacturing in the pharma sector.

According to Vision Research Reports, the insilico clinical trials market was estimated at USD 2.6 billion in 2021 and is expected to hit around USD 5.0 billion by 2030, registering growth at a CAGR of 7.3% from 2022 to 2030.

Based on a positive pre-IND meeting with the U.S. Food and Drug Administration (FDA), Ceruvia Lifesciences has submitted an Investigation New Drug (IND) application to begin a Phase 2 clinical trial for the treatment of obsessive-compulsive disorder with psilocybin.

Bitech Technologies Corporation today announces that the Company will participate in the upcoming LD Micro Invitational, a prominent 3-day investor conference on June 8, 2022.

PanTher Therapeutics (PanTher), a clinical-stage oncology company developing next-generation targeted therapies for solid tumors, today announced that a methods-of-use patent for a deployable anticancer drug-eluting stent, exclusively licensed to PanTher.

Nuvo Pharmaceuticals Inc. (TSX:MRV; OTCQX:MRVFF) d/b/a Miravo Healthcare (Miravo or the Company), a Canadian-focused healthcare company with global reach and a diversified portfolio of commercial products, today announced the appointment of Dale MacCandlish Weil to its Board of Directors (Board).

Sparrow Pharmaceuticals today presented new pharmacological data during a poster session and a Rapid Communications session.

IAMA Therapeutics, a preclinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel medicines to make a difference in the lives of individuals suffering from brain disorders, announced today it will deliver an oral presentation during the upcoming XXVII EFMC International Symposium on Medicinal Chemistry (EFMC-ISMC).

Rubius Therapeutics, Inc. (Nasdaq: RUBY), today announced the appointment of Noubar Afeyan, Ph.D., co-founder and member of the board of directors of Rubius Therapeutics and chief executive officer of Flagship Pioneering, as chairman of its board of directors.